iBio Inc (IBIO)
2.15
+0.30
(+16.22%)
USD |
NYAM |
May 02, 11:54
iBio Cash from Financing (Quarterly): 4.005M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.005M |
| September 30, 2023 | 2.472M |
| June 30, 2023 | 2.74M |
| March 31, 2023 | 1.464M |
| December 31, 2022 | -3.044M |
| September 30, 2022 | 1.141M |
| June 30, 2022 | -0.01M |
| March 31, 2022 | -0.01M |
| December 31, 2021 | -6.017M |
| September 30, 2021 | -0.088M |
| June 30, 2021 | 2.912M |
| March 31, 2021 | 4.738M |
| December 31, 2020 | 35.08M |
| September 30, 2020 | 36.10M |
| June 30, 2020 | 49.76M |
| March 31, 2020 | 10.29M |
| December 31, 2019 | 5.146M |
| September 30, 2019 | 0.00 |
| June 30, 2019 | -0.05M |
| March 31, 2019 | -0.05M |
| December 31, 2018 | 2.41M |
| September 30, 2018 | 1.143M |
| June 30, 2018 | 16.19M |
| March 31, 2018 | 0.075M |
| December 31, 2017 | 5.183M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.956M |
| June 30, 2017 | -0.044M |
| March 31, 2017 | -0.043M |
| December 31, 2016 | -0.042M |
| September 30, 2016 | -0.041M |
| June 30, 2016 | 4.002M |
| March 31, 2016 | 17.60M |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.063M |
| June 30, 2015 | 2.698M |
| March 31, 2015 | 2.09M |
| December 31, 2014 | 5.579M |
| September 30, 2014 | 0.50M |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 3.551M |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 3.834M |
| March 31, 2013 | 0.00 |
| December 31, 2012 | 0.00 |
| September 30, 2012 | |
| June 30, 2012 | 0.0002M |
| March 31, 2012 | 9.121M |
| December 31, 2011 | -0.0853M |
| September 30, 2011 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-6.017M
Minimum
Dec 2021
49.76M
Maximum
Jun 2020
7.717M
Average
2.472M
Median
Sep 2023
Cash from Financing (Quarterly) Benchmarks
| Lixte Biotechnology Holdings Inc | 0.00 |
| PAVmed Inc | 5.288M |
| Avalo Therapeutics Inc | 0.001M |
| Imunon Inc | 0.0302M |
| Ocugen Inc | 0.016M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -4.706M |
| Free Cash Flow | -18.89M |
| Free Cash Flow Per Share (Quarterly) | -2.536 |
| Free Cash Flow Yield | -768.3% |